<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LINEZOLIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LINEZOLIDE" rxcui="190376">
<ATC code="J01XX08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the linezolide by the clarithromycin, due to increase of its absorption</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LINEZOLIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LINEZOLIDE" rxcui="190376">
<ATC code="J01XX08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AM06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.</COMMENT>
</INTERACTION>
</INTERACTIONS>
